BuyCancerDrugs.com BuyCancerDrugs.com
BuyCancerDrugs.com BuyCancerDrugs.com
OncologyJournal.org - The Latest Medical News and Information for Patients Diagnosed with Cancer
Search OncologyJournal.org
Browse by Cancer Type or Cancer Drug

Go Back   OncologyJournal.org - The Latest Medical News and Information for Patients Diagnosed with Cancer > Blogs > admin
Connect with Facebook


Dasatinib
Old

Second-generation TKIs poised to succeed imatinib in newly diagnosed CML

Posted 08-10-2010 at 05:14 PM by admin
Oncology NEWS International. Vol. 19 No. 8
Focus on Hematology

Second-generation TKIs poised to succeed imatinib in newly diagnosed CML
By MARY BETH NIERENGARTEN | August 10, 2010

Imatinib (Gleevec), the first-line standard of care in chronic myeloid leukemia, will become a generic drug in 2015, so the race is on to find a second generation of tyrosine kinase inhibitors (TKIs) that can do the job just as well.

Dasatinib (Sprycel) and nilotinib (Tasigna)...
Administrator
Comments 0 admin is offline
Old

The Launch & Uptake of 9 Emerging Therapies Will Drive Prostate Cancer Drug Market

Posted 07-20-2010 at 04:05 PM by admin
The Launch and Uptake of Nine Emerging Therapies Will Drive the Prostate Cancer Drug Market to More Than Double to $8.4 Billion in 2019

Emerging Therapies, Most Notably Dendreon's Provenge, Will Account For More Than Half of the Total Prostate Cancer Market in 2019, According to Findings from Decision Resources

WALTHAM, Mass., July 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds...
Administrator
Comments 0 admin is offline
Old

Priority Rev. Schedule for BMS and Otsuka’s sNDA for Sprycel as 1st-Line CML Therapy

Posted 07-13-2010 at 03:31 PM by admin
Jul 12 2010

FDA Sets Priority Review Schedule for BMS and Otsuka’s sNDA for Sprycel as First-Line CML Therapy

FDA accepted an sNDA for Bristol-Myers Squibb (BMS) and Otsuka Pharmaceutical’s chronic myeloid leukemia (CML) drug, Sprycel®, and has granted the application priority review status. The sNDA specifically relates to use of the BCR-ABL inhibitor for the treatment of adult patients with newly diagnosed CML in chronic phase. The projected FDA action data is October...
Administrator
Comments 0 admin is offline
Old

UPDATE 1-Sprycel tops Gleevec in newly diagnosed CML-study

Posted 06-08-2010 at 03:07 PM by admin
Sun Jun 6, 2010 12:14am BST

* Sprycel cleared leukemia cells in 77 pct vs 66 pct

* Fewer side-effects than with Gleevec

* Novartis drug Tasigna tops Gleevec in similar study (Recasts, updates with quote from meeting)

By Bill Berkrot

NEW YORK, June 5 (Reuters) - Bristol-Myers Squibb's (BMY.N) cancer drug Sprycel was superior to the highly effective Gleevec in treating newly diagnosed patients with chronic myeloid leukemia, researchers...
Administrator
Comments 0 admin is offline
Old

UPDATE 1-Novartis' Tasigna beats Glivec in 18-mth study

Posted 06-04-2010 at 02:31 PM by admin
Fri Jun 4, 2010 3:52am EDT

* New data confirms previous 12-mth study in leukaemia

* Eyes on Phase III study from rival Bristol-Myer's Sprycel

* Sprycel and Tasigna vying for top spot in CML

ZURICH, June 4 (Reuters) - Swiss drug-maker Novartis (NOVN.VX) said 18-month results from a study confirmed its Tasigna cancer drug is more efficient in slowing down chronic myeloid leukaemia (CLM) than older medicine Glivec.

A previous study had...
Administrator
Comments 0 admin is offline


All times are GMT. The time now is 02:13 PM.


Powered by vBulletin® Version 3.8.1
Copyright ©2000 - 2010, Jelsoft Enterprises Ltd.